Drugs / AMX0114
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06665165 | Apr 2025 → Feb 2027 expected | amyotrophic lateral sclerosis | Amylyx Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMX0114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06665165 ↗ |
| Action | Inhibit | “AMX0114 is designed to reduce the levels of calpain-2” NCT06665165 ↗ |
| Route | Intrathecal | “AMX0114 will be administered once every 4 weeks by intrathecal bolus injection” NCT06665165 ↗ |